Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Health, Inc. (NASDAQ:JAGX) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 51,100 shares, a growth of 43.1% from the March 15th total of 35,700 shares. Approximately 9.2% of the company’s stock are short sold. Based on an average daily volume of 24,800 shares, the short-interest ratio is currently 2.1 days.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Jaguar Health in a research note on Friday, March 28th. They set a “sell” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Jaguar Health stock. Geode Capital Management LLC lifted its holdings in shares of Jaguar Health, Inc. (NASDAQ:JAGX) by 18.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 96,716 shares of the biotechnology company’s stock after buying an additional 14,895 shares during the period. Geode Capital Management LLC owned approximately 0.82% of Jaguar Health worth $98,000 at the end of the most recent reporting period. 12.04% of the stock is owned by hedge funds and other institutional investors.

Jaguar Health Stock Down 1.8 %

JAGX stock traded down $0.10 during trading on Friday, hitting $5.51. 10,340 shares of the company’s stock traded hands, compared to its average volume of 28,453. The company has a quick ratio of 1.36, a current ratio of 1.84 and a debt-to-equity ratio of 1.65. The stock has a fifty day moving average price of $10.90 and a two-hundred day moving average price of $20.54. Jaguar Health has a 52 week low of $4.02 and a 52 week high of $540.00.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.